Label-free Detection Market (2025-2032)
The Label-Free Detection Marketwas valued at $2.14 billion in 2024. This market is expected to reach $4.48 billion by 2032, from an estimated $2.33 billion in 2025, at a CAGR of 9.8% during the forecast period 2025-2032. Label-free Detection Market Size & Forecast The growth of this market can be
- Published
- Feb 2025
- Pages
- 320
- Format
- PDF + Excel
- Report ID
- MRHC - 10427
- Base year
- 2024
- 2024 · BASELINE
- $2.14B
- 2032
- $4.48B
- CAGR 2025–2032
- 9.8%
2024 baseline · 2025–2032 forecast at 9.8% CAGR · hover a bar for the value
Key highlights
By Product Type: In 2025, the Consumables Segment to Dominate the Label-free Detection Market
By Technology: In 2025, the Surface Plasmon Resonance (SPR) Segment to Dominate the Label-free Detection Market
By Application: In 2025, the Drug Discovery & Development Segment to Dominate the Label-free Detection Market
By Process: The Binding Kinetics Segment to Dominate the Label-free Detection Market
By End User: The Pharmaceutical & Biotechnology Companies Segment to Dominate the Label-free Detection Market
Report summary
| Particulars | Details |
|---|---|
| Number of Pages | 320 |
| Format | |
| Forecast Period | 2025–2032 |
| Base Year | 2024 |
| CAGR (Value) | 9.8% |
| Market Size (Value) | USD 4.48 Billion by 2032 |
| Segments Covered | By Product Type · Consumables · Biosensor Chips · Microplates · Kits & Reagents · Instruments · Optical Biosensor Instruments · Microcalorimeters · Other Instruments · Software · By Technology · Surface Plasmon Resonance (SPR) · Bio-Layer Interferometry (BLI) · Isothermal Titration Calorimetry (ITC) · Grating-Coupled Interferometry (GCI) · Differential scanning calorimetry (DSC) · Other Technologies · (Note: Other technologies include Optical Waveguide Grating Technology (OWGT), Microscale Thermophoresis (MST), and Electrical Impedance Spectroscopy (EIS). · By Application · Drug Discovery & Development · Vaccine Development · Gene Therapy Development · Biological Research · Other Applications · (Note: Other technologies include bioprocessing and impurity testing) · By Process · Binding Kinetics · Hit Confirmation · Lead Generation · Endogenous Receptor Detection · Binding Thermodynamics · Other Processes · (Note: Other technologies include end-point screening & specificity testing and affinity analysis.) · By End User · Pharmaceutical & Biotechnology Companies · Academic & Research Institutes · Contract Research Organizations |
| Countries Covered | North America (U.S., Canada), Europe (Germany, France, Italy, U.K., Spain, Switzerland, Rest of Europe), Asia–Pacific (India, China, Japan, Rest of Asia–Pacific), Latin America, Middle East & Africa. |
| Key Companies | Danaher Corporation (U.S.), PerkinElmer, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), GE HealthCare Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Sartorius AG (Germany), Corning Inc. (U.S.), Horiba, Ltd. (Japan), Malvern Panalytical Ltd (U.K.), and Bruker Corporation (U.S.). |
Report overview
Segments covered: product, technology, process, application, end user. Regions: North America, Europe.
The growth of this market can be attributed to several factors, including the high growth in the pharmaceutical and biotechnology market, government initiatives, rising R&D funding, and increasing adoption of innovative approaches in drug discovery. Moreover, technological advancements in label-free detection, growing applications of label-free detection in point-of-care testing, and emerging economies are expected to offer growth opportunities for the players operating in this market.
Report infographic
Market dynamics
5 factors across 3 forcesIncreasing adoption of Innovative Approaches in Drug Discovery
Rapid Growth in Pharmaceutical and Biotechnology Market
Table of contents
13 chapters · 120 sections · 320 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Product Type | Consumables | — |
| By Technology | Surface Plasmon Resonance (SPR) | — |
| By Application | Drug Discovery & Development | Gene therapy development |
| By Process | Binding Kinetics | — |
| By End User | Pharmaceutical & Biotechnology Companies | — |
By Product Type
- The Consumables Segment to Dominate the Label-free Detection Market
- The consumables segment is expected to account for the largest share of the label-free detection market.
- This segment's large market share is attributed to the recurring use of consumables, technological advancements in label-free detection technologies, and their increasing adoption for screening biomolecules and assays for accurate and easy diagnosis of disease and understanding the interaction of these assays with target molecules for drug discovery applications.
- The instruments segment is further segmented into optical biosensor instruments, microcalorimeters, and other instruments.
- The optical biosensor instruments segment is expected to account for the largest share of 78.4% of the label-free detection market.
- The large market share of this segment can be attributed to the benefits offered by optical biosensor instruments, such as the high sensitivity, direct and real-time measurement, in addition to multiplexing capabilities, which increases its adoption.
By Technology
- The Surface Plasmon Resonance (SPR) segment is expected to account for the largest share of the label-free detection market.
- The large market share can be attributed to the advancements in the SPF technology, including label-free measurement of biomolecular interactions, allowing for the real-time detection of biomolecules, and offering greater versatility compared to other technologies, increasing its adoption.
- Furthermore, growing demand for SPR systems; hence, companies are focusing on the introduction of innovative offerings.
- For instance, in April 2022, Sartorius AG (Germany) launched the Octet SF3, the Surface Plasmon Resonance (SPR) system, to offer real-time, label-free analysis of biomolecular interactions.
By Application
- The drug discovery & development segment is expected to account for the largest share of the label-free detection market.
- Label-free detection techniques offer high-throughput screening of various drug candidates for a wide range of target molecules and offer real-time molecular interactions, resulting in improved screening of massive compound databases.
- The capacity to quickly identify interesting lead compounds is the factor that boosts the demand for label-free detection in drug discovery.
- Furthermore, to cater to the growing demand for label-free detection technologies in drug discovery & development, companies are actively focusing on the introduction of innovative offerings.
- For instance, in February 2022, Bruker Corporation (U.S.) launched the timsTOF MALDI PharmaPulse (timsTOF MPP) system for label-free High-Throughput Screening (HTS) in drug discovery.
- However, the gene therapy development segment is projected to witness the highest growth rate of 16.7% during the forecast period of 2025–2032.
- This growth is driven by the increasing adoption of label-free detection technologies in gene therapy development.
By Process
- The Binding Kinetics Segment to Dominate the Label-free Detection Market
- The binding kinetics segment is expected to account for the largest share of the label-free detection market.
- The large market share of this segment can be attributed to the advancements in structural biology and the growing focus on personalized medicine.
- Further, to ensure efficacy and safety, biologics, including monoclonal antibodies, need to be properly characterized and tested in terms of binding kinetics.
- Label-free detection techniques provide a non-destructive and label-free method for examining complicated interactions, which makes them an excellent alternative for biological research.
By End User
- The pharmaceutical & biotechnology companies segment is expected to account for the largest share of the label-free detection market.
- The large market share of this segment can be attributed to the technological advancements that have increased the adoption of label-free technologies by the pharmaceutical & biotechnology companies, and product launches to expand the innovative offering.
- For instance, in June 2022, Agilent Technologies Inc. (U.S.) launched the LC/MS and GC/MS quadrupole mass spectrometers at the 70th ASMS Conference on Mass Spectrometry in Minnesota, U.S. This system offers an automated sample reinjection function to make simpler lab operations.
- Further, in February 2021, Creoptix (Switzerland) launched the waveRAPID, a label-free kinetic measurement method to increase productivity in the laboratory.
Geographic analysis
North America
Largest shareIn 2025, North America is expected to account for the largest share of 43.6% of the label-free detection market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America’s significant market share can be attributed to several key factors, including the presence of major label-free detection companies, increasing adoption of innovative approaches in drug discovery, and technological advancements in label-free detection technologies.
Asia-Pacific
Fastest growthMoreover, the market in Asia-Pacific is slated to register the highest growth rate of 13.2% during the forecast period. The growth of this regional market is attributed to the rising adoption of advanced label-free technologies in the pharmaceutical and biotechnology industries, increasing research activities, the presence of label-free detection consumables and instruments manufacturers in countries such as China, India, and Japan, technological advancements in label-free detection technologies, and increased awareness of label-free techniques.
Competitive landscape
- April 2022
Sartorius AG (Germany) launched the Octet SF3, a Surface Plasma Resonance (SPR) system that offers real-time, label-free analysis of biomolecular interactions.
- February 2022
Bruker Corporation (U.S.) launched the timsTOF MALDI PharmaPulse (timsTOF MPP) system for label-free High-Throughput Screening (HTS) in drug discovery.
- October 2021
Gator Bio, Inc. (U.S.) launched the GatorTM SMAP probe and GatorTM mFC probe for small molecule-protein kinetics and hybridoma screening.
- Danaher Corporation (U.S.)
- PerkinElmer, Inc. (U.S.)
- Agilent Technologies, Inc. (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- GE HealthCare Technologies, Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- Sartorius AG · Germany
- Corning Inc. (U.S.)
- Horiba, Ltd. · Japan
- Malvern Panalytical Ltd (U.K.)
- Bruker Corporation (U.S.)
Frequently asked questions
This study offers a detailed assessment of the label-free detection market and analyzes the market sizes & forecasts based on product type, technology, application, process, and end user. This report also involves the value analysis of various segments and subsegments of the label-free detection market at the regional and country levels.
Cite this report
Meticulous Research. (2025). Label-free Detection Market - Global Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MRHC - 10427). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/label-free-detection-market-3408